Beam Therapeutics/$BEAM
1D1W1MYTD1Y5YMAX
Capital at risk
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
- Ticker
- $BEAM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 540
- Headquarters
- Cambridge, United States
- Website
- beamtx.com
BEAM Metrics
BasicAdvanced
$2.5B
-
-$0.84
2.21
-
Price and volume
Market cap
$2.5B
Beta
2.21
52-week high
$38.26
52-week low
$20.23
Average daily volume
1.8M
Financial strength
Current ratio
14.572
Quick ratio
14.254
Long term debt to equity
0.217
Total debt to equity
0.232
Profitability
EBITDA (TTM)
-355.781
Gross margin (TTM)
-161.91%
Net profit margin (TTM)
-55.45%
Operating margin (TTM)
-242.27%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-17.01%
Return on equity (TTM)
-8.18%
Valuation
Price to revenue (TTM)
16.516
Price to book
2.34
Price to tangible book (TTM)
2.34
Price to free cash flow (TTM)
-6.914
Free cash flow yield (TTM)
-14.46%
Free cash flow per share (TTM)
-3.609
Growth
Revenue change (TTM)
158.88%
Earnings per share change (TTM)
-81.28%
3-year revenue growth (CAGR)
24.86%
3-year earnings per share growth (CAGR)
-42.97%
What the Analysts think about BEAM
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
Analyst projections of the future price of Beam Therapeutics stock.
Bulls say / Bears say
BEAM-302 delivered strong early biomarker results, with 60 mg producing mean total AAT of 16.1 µM, 94% corrected M-AAT, and an 84% reduction in mutant Z-AAT, with durability observed through as long as 12 months. The program has advanced into a global pivotal cohort and may pursue accelerated approval based on biomarkers. (Nasdaq)
Risto-cel is approaching a potentially important regulatory inflection point: dosing is complete for all adult and adolescent BEACON participants, with updated data and a U.S. BLA submission expected as early as year-end 2026. (SEC)
Beam ended Q2 2026 with approximately $1.2 billion in cash, cash equivalents, and marketable securities, which management expects—alongside planned credit-facility funding—to support operations into mid-2029. The FDA’s clearance of the BEAM-304 IND also broadens the pipeline into PKU while BEAM-301 advances in GSDIa. (SEC)
BEAM-302’s encouraging results remain based on a small, early-stage dataset: 29 patients were treated, and the multi-dose cohort included serious liver-enzyme elevations, including one Grade 4 ALT and Grade 3 AST event. Larger pivotal testing could reveal weaker durability or safety. (Nasdaq)
Beam remains deeply loss-making, reporting a $122.7 million net loss in Q2 2026 versus $102.1 million a year earlier. Its projected cash runway into mid-2029 also assumes drawing an additional $200 million under a credit facility, adding financing and execution dependence. (SEC)
The principal value drivers are still unapproved and dependent on future milestones: risto-cel’s BLA is targeted only as early as year-end 2026, while BEAM-302 requires pivotal enrollment and BEAM-304 is just entering clinical development. Delays, regulatory setbacks, manufacturing problems, or adverse events could materially impair the equity story. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
BEAM Financial Performance
Revenues and expenses
BEAM Earnings Performance
Company profitability
Upcoming events
No upcoming events
BEAM News
AllArticlesVideos
Funds containing BEAM
AllUSDGBPEUR
Fund name | Fund size | $BEAM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.17% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.